I've seen a lot of talk on this and I want to clear this up, so people can stop getting ripped off.
If you want to research too, here's the link to this study I quoted: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347663/#!po=4.02299
Now you can have fun like Jbry used too! :banana:
Pharmacological investigations into the biological role of the REV-ERBα have used the sub-optimal chemical probe GSK4112 (1) and, its analogs SR9011 (2) and SR9009 (3)(Figure 1).10,11
The IV and oral DMPK profiles of compounds 3(SR9009), 4, 10, 16, and 23 were evaluated in a 1 mg/Kg cassette dose experiment in C57Bl/6 mice. Four of the compounds demonstrated essentially identical profiles with short half-lives, high clearance, and low oral bioavailability. Compound 4 (GSK2945) was differentiated from the group with a longer half-life of 2.0 h and an oral bioavailability of 23%,
For those that wondered what Jbry did at Olympus an other companies, he spent his free time researching compounds like this!The remaining four compounds (3(SR9009), 10, 16, 23) would be suitable for acute time-of-day dosing by injectionwhere short exposure of the compound at meaningful levels in desired.
If you want to research too, here's the link to this study I quoted: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347663/#!po=4.02299
Now you can have fun like Jbry used too! :banana: